MNKD实时信号 | 通过Getagraph.com最大化利润

出售 111212 min ago

@ $3.58

发出时间: 15 Feb 2024 @ 03:32

回报率: 21.40%

上一信号: Feb 15 - 02:57

上一信号: 购买

回报率: 1.56 %

Live Chart Being Loaded With Signals

Commentary (2 May 2024 @ 04:00):

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States...

Stats
今日成交量	2.51M
平均成交量	2.92M
市值	1.17B
EPS	$0 ( 2024-02-27 )
下一个收益日期	( $0.0200 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-108.50
ATR14	$0.00800 (0.18%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-22	Prentiss Christopher B	Buy	0
2024-03-27	Sabella Lauren M	Sell	17 084	Common Stock, $.01 Par Value
2024-02-04	Tross Stuart A	Buy	15 290	Common Stock, $0.01 Par Value
2023-12-31	Tross Stuart A	Buy	1 006	Common Stock, $0.01 Par Value
2023-06-30	Tross Stuart A	Buy	4 012	Common Stock, $0.01 Par Value

INSIDER POWER
30.57
Last 95 transactions
Buy: 5 237 724 \| Sell: 2 722 728

音量相关性

長: -0.05 (neutral)

短: -0.92 (very strong negative)

Signal:(44.318) Neutral

MannKind Corp 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

MannKind Corp 相关性 - 货币/商品

0.23
( neutral )

0.07
( neutral )

0.00
( neutral )

-0.11
( neutral )

-0.25
( neutral )

MannKind Corp 财务报表

Annual	2023
营收:	$198.96M
毛利润:	$136.19M (68.45 %)
EPS:	$-0.0447

FY	2023
营收:	$198.96M
毛利润:	$136.19M (68.45 %)
EPS:	$-0.0447

FY	2022
营收:	$99.77M
毛利润:	$42.27M (42.37 %)
EPS:	$-0.440

FY	2021
营收:	$75.44M
毛利润:	$36.59M (48.49 %)
EPS:	$-0.320

Financial Reports:

No articles found.

MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.